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Between March 3, 1981, and June 1, 1984, 216 children were evaluated for 
orthotopic liver transplantation. Of the 216 patients, 117 (55%) had received at 
least one liver transplant by June 1, 1985. Fifty-five (25%) died before transplan-
tation. The 117 patients who received transplants were grouped according to 
severity of disease and degree of general decompensation at the time of 
transplantation. The severity of a patient's medical condition with the possible 
exception of deep hepatic coma, did not predict outcome following orthotop-
Ic liver transplantation. Seventy variables were assessed at the time of the 
evaluation. Twenty-three of the 70 variables were found to have prognostic 
significance with regard to death from progressive liver disease before trans-
plantation. These 23 variables were Incorporated into a multivariate model to 
provide a means of determining the relative risk of death among pediatric 
patients with end-stage liver disease. This information may allow more 
informed selection of candidates awaiting liver transplantation. (J PEDIATR 
1987;111:479-89) 
Number 4 
The advent of cyclosporine and advances in surgical 
technique changed the status of orthotopic liver transplan-
tation from an experimental procedure to accepted care for 
lethal liver disease. I As I-year survival probabilities 
approached 66% of OL Tx recipients in late 1981 and early 
1982,2 the question of who should receive the next available 
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organ took on critical importance. The improvement in 
success of OL Tx increased the number of children referred 
for the procedure. More referrals not only sparked an 
increase in transplantation but drew attention to the 
shortage of available organs.3 Twenty-five percent of 
referred children died of progressive liver disease before 
transplantation because an appropriate organ could not be 
located. Donated organs became a precious resource, and 
their utilization demanded a logical approach to recipient 
selection. 
The process of selecting a recipient when a donor liver 
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ALT 
OLTx 
PT 
PTPK 
PTT 
Alanine aminotransferase (SGPT) 
Orthotopic liver transplantation 
Prothrombin time 
Prothrombin time 24 hours after parenteral 
administration of vitamin K (5 to 10 mg) 
Partial thromboplastin time 
becomes available is determined primarily by matching the 
donor and recipient according to size and according to 
ABO blood group. conforming to blood banking rules of 
blood transfusions" In situations of great urgency, even 
ABO incompatibility may be disregarded as a condition 
for donor recipient matching.s No attempt to match minor 
red cell antigens or Rh factor is made. Extensive tissue 
typing is not performed because of time constraints; and it 
appears from retrospective analysis that it may be unnec-
essary"'s A number of appropriately matched potential 
recipients may exist for each donated organ. We attempted 
to determine whether providing a transplant for the sickest 
available potential recipient has an adverse effect on 
transplantation outcome. and second. to develop criteria to 
distinguish the sickest patient among those with heteroge-
neous but lethal liver diseases. 
METHODS 
Between March 3. 1981. and June 1. 1984. 216 pediatric 
patients were evaluated for OLTx (Table I). Follow-up for 
the purpose of this study extended to June I. 1985. 
Evaluation generally consisted of a 3- to 4-day hospitaliza-
tion during which six areas were assessed: (1) confirmation 
of the diagnosis of lethal liver disease, (2) assessment of 
severity and rate of progression. (3) assessment of compli-
cations. (4) confirmation of anatomic suitability for trans-
plantation. (5) psychosocial evaluation of the family and 
child. and (6) education of the family and child about liver 
transplantation. Details of this evaluation have recently 
been published.) 
Of the 216 patients. 117 had received at least one 0 L Tx 
as of June 1, 1985, the majority (107) at our institution 
and the remainder (10) at one of four other institutions. 
Fifty-five (25%) patients died before transplantation. For-
ty-four (20%) patients either await transplantation (22) or 
were deemed noncandidates (22) at the time of the 
evaluation and had survived to June 1. 1985. 
Phase 1. The study was conducted in two phases. During 
phase 1 the 117 patients who received transplants were 
retrospectively grouped according to clinical status at the 
time of transplantation (Table II). Group 1 comprised 
patients who were known to have either severe liver disease 
or a disease with a downhill course but who were clinically 
stable. This group of patients had received no medical 
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therapy for liver disease or its complications. aI-Antitryp-
sin deficiency with compensated cirrhosis or biliary atresia 
with a failed Kasai procedure (but early in the post-Kasai 
course) are typical of this group. A third subgroup in group 
I included patients with hepatic malignancy with metabol-
ic liver disease who did not have end-stage liver disease. 
Some patients with tyrosinemia would fit in this third 
subgroup. 
Group 2 consisted of children residing at home and 
receiving outpatient medical management. They had had 
no life-threatening complications of liver disease. Typically 
they were receiving choleretic, antipruritic. and diuretic 
therapy. 
Group 3 patients had accelerating decompensation of 
liver disease. These patients were either hospitalized 
because of complications of liver disease at the time of 
transplantation or had been repeatedly hospitalized in the 
recent past because of complications and were home at the 
time of transplantation. 
Group 4 patients were confined to the intensive care unit 
because of complications of liver disease. This group was 
the most heterogeneous. and included patients with active 
variceal hemorrhage receiving pitressin and blood transfu-
sions. patients with renal failure secondary to hepatorenal 
syndrome, and patients with grade 1-3 encephalopathy. 
Finally, group 5 included patients with stage 4 hepatic 
coma. These patients were responsive only to deep pain. 
with nonpurposeful reaction (decerebrate posturing) and 
oculocephalic and oculovestibular responses. 
Survival curves for the four groups were created using 
the actuarial method of Cutler and Ederer'i' 1 (Fig. 1). The 
life tables from which these curves were derived were 
compared by logrank statistics.1• 8 
Phase 2. Phase 2 of the study utilized the data collected 
for patients during evaluation for OL Tx to clarify which 
factors are predictive of imminent death from progressive 
liver disease so that the candidates with most urgent need 
of OL Tx could be identified. The evaluation data consisted 
of 70 variables· obtained in each of the 216 patients. from 
history. physical examination. and laboratory data. Vari-
ables were screened for their prognostic significance rela-
tive to death from progressive liver disease by methods 
suggested by Byar.9 
Historical data were recorded as yes or no responses to 
questions (e.g., Does the patient have a history of enceph-
alopathy? Does the patient have a history of ascites?). 
Physical examination findings were categorized as either 
ordinal data in the normal or increasingly abnormal range 
·The 70 variables assessed have been tabulated. and can be obtained 
from the National Auxiliary Publication Service. c/o Microfiche Publica-
tions. P.O. Box 3513, Grand Central Station, New York, NY 10013. 
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(e.g., spleen size normal [0], enlarged [I], or massively 
enlarged [2], on the basis of centimeters below the left 
margin) or nominal data recording the abnormality 
(e.g., cardiac examination revealing diastolic mur-
Laboratory data were grouped by choosing cut 
within the range of values of a given variable. Cut 
delineating such groupings were chosen either 
they had pathophysiologic significance or because 
resulted in an even distribution of patients in the 
response groups. For example, patients with serum 
sodium concentration :s 136 mEq/L were grouped togeth-
'er because this value represented a value below the 
physiologic range, whereas patients with AL T <80 IV, 80 
to 150 IV, and> 150 IV defined three response levels with 
approximately 72 patients in each group. Whenever a 
continuous variable was treated as categorical, the variable 
was also evaluated continuously to ensure that the group-
ing did not alter its prognostic importance. 
Average death rates (deaths per 1000 patient-months) 
were estimated at each response level for each variable. 
Estimates of the relative risk of death of patients in' one 
level versus those in another were obtained using the Cox 
proportional hazards model. 10 The death rale, for example, 
in patients with a history of ascites was 45.1, compared 
, with 6.9 in those without a history of ascites. Using the 
Cox model, the estimated risk of dying was 5.2 times 
greater among patients with ascites than without ascites. 
The p value for the comparison of the curves at each 
response level for a given variable were then obtained using 
the log-rank statistic.s Comparison of the two survival 
curves (Fig. 2) for patients with and without a history of 
ascites revealed the curves to be statistically different (P 
<0.0001). 
. y.",.' 
Each of the 70 variables was examined in this fashion. 
Variables found to have prognostic significance were 
tabulated with their response levels, number of patients, 
number of patient deaths, follow-up months, death rate (as 
previously defined), risk, and P value. A potential source of 
error in evaluating the 70 variables lies in our bias toward 
providing transplants for patients who, in our perception, 
had the most advanced disease. II Consequently, to evaluate 
whether this bias had influenced the variables indicating 
prognostic importance for pretransplantation survival, we 
assessed the same variables in a subset of patients exclud-
ing those undergoing transplantation. Finally, the vari-
ables of prognostic significance before transplantation 
were used to develop a multivariate model of overall 
patient risk of death related to progressive liver disease. 
RESULTS 
Impact of recipient medical condition on outcome. The 
survival curves for the four clinical status groups flattened 
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Table I. Liver transplantation evaluations: March 3, 
1981, to June I, 1984 
481 
No. of 
patients 
Extrahepatic biliary obstruction 
Extrahepatic biliary atresia 
Choledochal cyst 
Benign tumor 
Liver-based metabolic error 
Alpha-I-antitrypsin deficiency 
Wilson disease 
Tyrosinemia 
Glycogen storage disease I 
Glycogen storage disease IV 
Chronic hepatitis 
Chronic active hepatitis non A non B 
Neonatal hepatitis 
Chronic active hepatitis. lupoid 
Cholestatic disease 
Familial cholestasis 
Cystic fibrosis 
Lysosomal enzyme defect 
Sea blue histiocyte syndrome-
Wolman diseaset 
Miscellaneous 
Biliary hypoplasia 
Congenital hepatic fibrosis 
Idiopathic cirrhosis 
Trauma 
Hepatoma 
Lymphangiomatosis 
110 
3 
29 
5 
4 
1 
10 
9 
2 
10 
20 
3 
2 
"This child with sea blue histiocyte syndrome (neurovisceral storage disease 
with supranuclear ophthalmoplegia) had cirrhosis and hepatoma complicat-
ing the baSIC disease; her metabolic disease has not been cured." 
tThis child with Wolman disease was deemed a noncandidate because we 
thought liver transplantation would not alter the disease. 
after sloping downward during the first postoperative 18 
months (Fig. 1). Final survival over the study period was 
85% for group 1,74% for group 2, 81% for group 3, and 
77% for group 4. Clinical status group 5 contained only one 
patient and was not included in this evaluation. The 
survival curves of groups I through 4 were not statistically 
different (P = 0.9). 
Pretransplantation risk of death 
All patients. Twenty-three of the 70 variables had 
prognostic significance relative to death caused by progres-
sive liver disease (Table III). These variables with 
responses are defined in more detail in Clinical Appendix 1. 
The variables generally had a predictive relationship to 
early death from progressive liver failure that might be 
expected. However. a few of the variables had unexpected 
relationships. Age had no statistically significant prognos-
tic value. A number of laboratory values (ALT, gamma 
-- K-K-"K-~-~-----
482 Malatack et al. 
Table II. Clinical data 
Sex Mean age 
Clinical status group (M/F) (yr) 
Patient residing at home; no 2/5 5.34 
therapy (n = 7) 
2 Patients residing at home; 33/34 1.85 
outpatient medical management 
(e.g., phenobarbital. 
spironolactone) (n = 67) 
3 Patients with recent history of 9/23 5.77 
repeated hospitalizations with 
complications of liver disease. or 
hospitalized with complications 
of liver disease at time of 
transplantation (n = 32) 
4 Patients requiring intensive care SIS 9.8 
at time of transplantation 
(n = 10) 
5 Patients with stage 4 hepatic 0/1 9.5 
coma (n '" I) 
glutamyl transpeptidase, alkaline phosphatase) had a 
direct relationship with survival. Higher. more abnormal 
values were seen in patients with longest survival. Other 
variables (serum cholesterol and indirect bilirubin concen-
trations) had an unexpectedly strong correlation with 
survival. Serum cholesterol <100 mg/dL was the strongest 
predictor of early death. Elevation of indirect bilirubin was 
a stronger predictor of death than was elevation of direct 
bilirubin. 
Patients .without transplants. The results for the 23 
variables when the patients with transplants were elimi-
nated from the analysis generally agreed closely with the 
results when all patients were included (Table III). All 
variables remained statistically significant (P <0.05), and 
only one variable showed a decrease in risk of more than 
25% (the risk coefficient for serum chloride <i.0ncentration 
decreased from 9.1 when all patients were considered to 
5.7 when only patients without transplants were consid-
ered). 
Multivariate model. Once univariate analysis had estab-
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No. of No.ot 
Disease pallents deaths 
ai-Antitrypsin deficiency 2 I 
Biliary atresia 2 0 
Biliary hypoplasia 0 
Tyrosinemia 0 
Sea blue histiocyte syndrome 0 
Biliary atresia 39 10 
Biliary hypoplasia 9 4 
Familial cholestasis 6 3 
ai-Antitrypsin deficiency 5 I 
Chronic active hepatitis. non-A non- B 3 0 
Tyrosinemia 2 0 
Neonatal hepatitis 2 0 
Congenital hepatic fibrosis 1 0 
Biliary atresia 14 3 
ai-Antitrypsin deficiency 8 0 
Chronic active hepatitis. non-A non-B 3 I 
Familial cholestasis 2 0 
Glycogen storage disease I 0 
Choledochal cyst 
Neonatal hepatitis 0 
Biliary hypoplasia I 
Benign tumor I 
Biliary atresia 4 2 
ai-Antitrypsin deficiency 2 0 
Chronic active hepatitis. lupoid 0 
Chronic active hepatitis. non-A non-B I 
Wilson disease 0 
Familial cholestasis 0 
Wilson disease I 
ill 29 
lished the 23 variables of pretransplantation prognostic 
significance, they were evaluated in multivariate fashion to 
assess their joint prognostic importance. First, variables 
that could be easily altered by the medical caretaker (Na, 
Cl, Ca, pH) were eliminated (Clinical Appendix II). Next, 
variables associated with the highest risk were reviewed. 
Seven variables had risks in excess of 5 at their highest risk 
level. The seven variables were reduced to four (cholester-
ol, PIT, history of ascites, indirect bilirubin) on clinical 
grounds by eliminating those that gave redundant informa-
tion. PTT was chosen over PT and PTPK because it has the 
strongest predictive value of those variables measuring 
coagulation. Cholesterol was chosen over serum albumin 
because it has the strongest predictive value of those 
variables measuring synthetic function and nutritional 
state. 
The four variables were placed in the multiplicative 
exponential model (Statistical Appendix II). Each of the 
remaining variables and the three "redundant" variables 
were then added to the four in an attempt to improve the 
7 
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Fig. 2. Comparison of survival curves for patients with positive and negative histories of ascites. N. number of patients at 
risk. 
prognostic capability of the multivariate model. No further 
improvement in the model was achieved with any of the 
added variables. Thus these four variables with the five 
response levels (indirect bilirubin at 3 to 6 mg/dL and >6 
mg/dL response levels) provided much of the prognostic 
information that is available from the original 23 variables. 
An algorithm for selection of patients was determined by 
fitting the model to the 153 patients for whom all four 
variables were known. 
The multiplicative exponential model was used to devel-
op survival curves predictive of a patient's probability of 
survival over a given time. Fig. 3 shows survival curves of 
patients at high, moderate, and low risk. Patients at high 
risk were defined as those whose risk of dying within 6 
months of evaluation was greater than 75%; moderate risk, 
25% to 75%; and low risk, less than 25%. Fig. 3 also 
illustrates the observed survival curves for patients in the 
three risk groups. The moderate risk curve was consistently 
above the moderate risk actuarial curve, but there was 
otherwise close approximation of the model's predictive 
curves to the actuarial curves. The characteristics of 
patients in the three risk groups are given in Table IV. 
Based on the fitted model, it was possible to determine 
scores that give the relative importance of each of the 
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Table III. Twenty-three variables of prognostic significance 
Duration of 
No. of No. of follow-up Death 
pallents deaths (mo) rate" Risk Pt 
Historical data 
Gastrointestinal blccding 
:-.10 bic:eding 121 24 1521.0 15.8 
Acute variceal bleeding 45 16 314.6 50.9 2.39 0.02 
Other bleeding 50 15 482.3 31.1 1.81 
Ascites 
No 90 9 1297.4 6.9 <0.0001 
Yes 126 46 1020.5 45.1 5.2 
Coagulopathy 
:-.10 152 30 1872.5 16.0 <0.0001 
Yes 64 25 445.4 56.1 3.2 
Encephalopathy 
No 195 47 2189.7 21.5 0.005 
Yes 21 8 128.3 62.4 2.8 
Laboratory data 
Prothrombin time (sec prolonged) 
Normal 142 22 1891.6 11.6 <0.0001 
3-5 29 9 208.3 43.2 3.0 
>5 45 24 218.0 110.1 7.7 
Prothrombin time after vitamin K 
(sec prolonged) 
Normal 151 24 2014.6 11.9 <0.0001 
3-5 26 II 130.8 84.1 4.77 
>5 39 20 172.5 116.0 8.02 
Partial thromboplastin time 
(sec prolonged) 
Normal 181 35 2212.2 15.8 <0.0001 
10-20 17 7 60.6 115.6 5.5 
>20 17 12 42.9 279.7 11.6 
Alanine aminotransferase (SGPT) 
(lUlL) 
<80 71 27 663.3 40.7 0.0032 
80-150 73 19 888.5 21.4 57 
>150 71 9 762.6 11.8 .30 
-y-Glutamyl trans peptidase (lUlL) 
<100 67 24 433.1 55.4 0.0001 
100-280 71 17 740.0 23.0 .47 
>280 73 II 1116.7 9.9 .23 
Alkaline phophatase (mg/dL) 
<450 68 25 523.2 47.8 0.0002 
>450 144 29 1788.8 16.2 .38 
Bilirubin (mg/dL) 
Direct 
<5 74 12 1196.5 10.0 
5-10 61 11 620.6 17.7 1.5 <0.0001 
>10 81 32 500.8 63.9 4.7 
Indirect 
<3 84 10 1280.5 7.8 <0.0001 
3-6 52 14 573.8 24.4 2.8 
>6 79 31 462.2 67.1 6.4 
Total protein (g/dL) 
<7 114 40 1003.1 39.9 3.4 <0.0001 
... >7 97 13 1299.3 10.0 
"Deaths per 1000 patient-months. 
tComparison of survival curves by log-rank statistics. 
No. of No. of 
patients deaths 
Albumin 
>4 49 6 
3-4 92 18 
<3 72 31 
Cholesterol (mg/dL) 
<100 18 12 
>100 136 24 
Sodium (mEq/L) 
>136 140 22 
<136 76 33 
Chloride (mEq/L) 
<97 21 14 
>97 194 40 
Calcium (mEq/L) 
>8.5 121 16 
<8.5 82 35 
pH 
<7.38 60 16 
7.38-7.42 60 7 
>7.42 64 24 
Upper gastrointestinal tract 
Normal 90 13 
Varices 48 13 
Extensive varices 32 14 
Bone x-ray 
Normal 88 II 
Osteoperosis / rickets 106 36 
NH, (llg/dL) 
<100 177 38 
Fasting 
>100 18 9 
WBC (fmm') 
<5800 72 II 
580-1200 101 25 
>12,000 42 19 
prognostic variables (Table V). The total scores for 
patients in the low-risk group ranged from 0 to 27: from 28 
to 39 in the medium risk group; and from 40 to 55 in the 
high-risk group. 
DISCUSSION 
Prior to this study, the approach to selection of recipi-
ents for liver transplantation was unclear. One approach 
would utilize transplantable organs in patients with the 
most advanced liver disease because these patients would 
be least likely to survive until another organ becomes 
available. Alternatively, transplantable livers could be 
used in patients with more stable conditions, with the 
rationale that this group of patients might be more likely to 
Survive the rigors of surgery and thus benefit from the 
Choice of liver transplant recipients 485 
Duration of 
follow-up Death 
(mO') rate' Risk Pt 
765.7 7.8 <0.0001 
1027.6 17.5 \.9 
505.5 61.3 5.7 
36.1 332.4 14.3 <0.0001 
1770.1 13.5 
1771.1 12.4 <0.0001 
546.9 60.3 4.3 
59.3 236.1 9.1 <0.0001 
2257.1 17.7 
1680.6 9.5 <0.0001 
552.2 63.4 5.2 
630.8 25.4 2.54 0.008 
722.2 9.7 
658.8 36.4 3.55 
1250.5 10.4 0.0008 
401.9 32.3 2.5 
288.6 48.5 3.9 
1089.6 10.1 0.0009 
1081.0 33.3 3.0 
1972.3 19.3 0.0008 
121.2 74.2 3.27 
881.5 12.5 0.0006 
1065.7 23.5 1.7 
370.6 51.3 3.78 
organ. It was necessary to know which of these two 
approaches would optimize the number of survivors from 
the group of patients waiting for transplants. 
Phase 1 of our study revealed no significant difference 
in mortality among the various clinical status groups, 
suggesting that the rationale for giving transplants to the 
most stable patients first is incorrect. The immediate 
implication is the necessity to give a transplant to the 
"sickest" patients in clinical status groups 1 through 4. 
This implication is not, however, without uncertainty. Our 
series is the largest to date, but the number of patients in 
the clinical status groups mandates some caution when 
interpreting the lack of significant difference. ll Groups 1 
and 4 were small, and even in groups 2 and 3, which were 
much larger, the chance of detecting a twofold difference 
486 Malatack et al. 
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in death rate was only approximately 50%. Consequently, 
continued investigation of the impact of the recipient's 
medical condition on transplantation outcome is impera-
tive.* 
There was only one patient in clinical status group 5 
(stage 4 hepatic coma), and she was not included in this 
analysis. In that one patient, OL Tx was technically suc-
cessful, but she never regained neurologic function and was 
subsequently declared brain dead. The experience with 
adult patients in similar clinical condition reveals a high 
immediate posttransplantation mortality.ll.14 This high-
risk group deserves special consideration. The decision to 
proceed with transplantation must be individualized. Phy-
sicians must consider both the relative urgency for surgery 
among other candidates who also match the available 
organ, and the likelihood that another organ of similar size 
and blood type will become available in the near future 
(some sizes and blood types are more difficult to obtain 
than others). 
Although our data suggest that survival outcome is not 
dependent on the patient's medical condition at the time of 
transplantation; the medical effort to get the sickest 
patients successfully through transplantation may be 
greater. There are other compelling reasons for a trans-
plantation before severe decompensation of liver disease. 
First, the children with the most advanced disease have a 
"The "National Institutes of Health if presently developing a Liver 
Transplantation Data Base to examine. among many issues. candidate 
selection. 
greater degree of growth failure than do their less sick 
counterparts. Second, these sickest children have more 
developmental delay as a direct result of both the disease 
(e.g .. chronic hyperammonemia, nutritional deprivation) 
and the medical response to that disease ll (frequent and 
prolonged hospitalizations). Third. emotional disturbances 
in these chronically ill children, related to altered parent-
child relationships. are more frequent. l • Finally, even in 
patients not apparently in extremis, sudden decompensa-
tion leading to death before transplantation is always a 
riskY Thus, although this study delineates the necessity of 
providing a transplant for the sickest available patients 
(with the possible exception of those with stage 4 hepatic 
coma), no patient should have to wait until advanced 
disease has evolved if the opportunity for transplantation 
presents itself earlier. 
Phase 2 was undertaken to develop a system to identify 
the sickest candidates through review of their evaluation 
data. The 23 variables with prognostic significance are, for 
the most part, those that an experienced clinician would 
expect. ALT elevation as an indicator of liver injury, and 
gamma glutamyl trans peptidase and alkaline phosphatase 
as indicators of cholangiopathy were of little predictive 
value compared with factors directly measuring residual 
hepatic function (e.g., PT, PIT, cholesterol) or altered 
physiology secondary to advanced liver disease (e.g., asci-
tes, hypochloremia). An unexpected prognostic variable 
was elevated leukocyte count. This elevation did not appear 
to be related to acute or chronic infection. Possibly it is the 
result of hepatocellular necrosis, analogous to the leukocy-
T· 
IV. Distribution of patients according to risk group 
Risk group 
Low Moderate High 
13 13 9 
Alive 98 16 4 
64 2 0 
Yes 47 27 13 
Bilirul:)in, indirect (mg/dL) 
<3 60 0 
3-6 36 0 3 
>6 15 28 10 
Cholesterol (mgjdL) 
<100 3 13 
>100 110 26 0 
Partial thromboplastin time 
(sec prolonged) 
<20 109 27 9 
>20 2 2 4 
Table demonstrates distribullon of prognostic factors across risk groups. 
Note increase in number of poor prognostic faclors in high-risk group. 
seen in alcoholic hepatitis, I' thus explaining its 
. 'p with death from progressive liver failure. i: Houssin and Franco" attempted to clarify criteria for 
liver transplantation from clinical data collected from June 
1973 to December 1977 in adult patients with cirrhosis. At 
that time, mortality following liver transplantation was 
. excessive, and the decision to go forward with liver 
transplantation seemed reasonable only in those patients 
with short expected survival. Thus.criteria that predicted a 
. high likelihood of dying in the subsequent month were 
determined. Since the development of cyclosporine,20 sur-
vival after liver transplantation has dramatically 
improved2 •• and transplantation in less critically ill patients 
has become accepted. In our series, survival after trans-
- plantation (76%) equaled the percent survival from evalu· 
ation until transplantation (75%), making death from 
progressive liver failure the highest risk for the pediatric 
m~K patient awaiting transplantation. Phase I of our study 
~i:D:DI suggested that the patient's medical condition at the time 
, of transplantation (except perhaps stage 4 hepatic coma) 
lacked a significant detrimental impact on transplantation 
outcome and crystallized the importance of identifying the 
sickest patient. Phase 2 provided an approach to the 
identification of the sickest patient awaiting transplanta-
tion. These sickest patients are in urgent need of transplan· 
tation, not as in Houssin's patients in whom there was 
nothing to lose, but because there is everything to gain. 
The multivariate model developed in our study provides 
One means of identifying the sickest patient with advanced 
liver disease. This model has been demonstrated to be 
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Table V. Prognostic scores for risk of death 
Weighting lactor 
+15 
+15 
+13 
+11 
+10 
Variable 
If cholesterol <100 mg/dL 
If positive history of acites 
If bilirubin indirect >6 mg/dL 
If bilirubin indirect 3-6 mg/dL 
If PTT prolonged >20 sec 
Total patient score of 0-28 places patient in low-risk group (Fig. 4); 
28-39, moderate risk group; 2:40. high-risk group. 
internally consistent in that actuarial data from which the 
model was derived and the predictions of the model have 
close correlation. This or a similar model now needs to be 
applied to patient data from multiple other institutions to 
support its predictive value. 
We recommend that pediatric patients accepted as 
candidates for transplantation be allocated to a high-, 
moderate-, or low-risk group on the basis of the four 
factors in our multivariate model. When a transplantable 
organ becomes available, those patients who are size and 
blood type matched to the donor and are in the highest risk 
category should be considered for transplantation first, 
the~ those patients at moderate risk, and finally patients 
considered to be at low risk. 
We recommend that data for at least the four variables 
used in the multivariate model be collected every 3 to 4 
months in candidate patients so that reassessment of risk 
can be made. By 3 to 4 months after evaluation, most 
patients in the high-risk group either will have died or will 
have received transplants, and newly evaluated patients as 
well as patients previously in the low- and moderate-risk 
groups will make up a new high-risk group in urgent need 
of transplantation. At centers with large numbers of 
pediatric patients on the candidate list, and where the 
high-risk group has multiple patients of similar size and 
blood type, then data for a portion or all of the 23 variables 
of prognostic significance should be collected at 3 to 4 
month intervals to aid in assessment of patient risk. The 
physician's ability to identify the sickest patient among the 
candidates allows the most appropriate child to be selected 
as a transplant recipient. This approach, which apparently 
will not increase transplantation deaths, will simultaneous-
ly decrease patient deaths from progressive liver failure. 
In addition to providing a means of choosing a candidate 
patient for liver transplantation within a center, extension 
of a model of this type may guide organ sharing among 
regional centers whose geographic borders would be 
defined by the time limit dictates of present methods of 
liver preservation. Ultimately, with improved preservation 
methods, a model of this type may provide a means of 
national organ allocation. 
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CLINICAL APPENDIX 
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I. Responses to historical and laboratory variables. The possible 
responses to historical variables and to various laboratory vari-
ables are defined. in the order of their appearance in Table Ill. 
A positive history of gastrointestinal bleeding was subdivided 
into patients with a history of acute variceal hemorrhage and those 
with other bleeding, generally stomal bleeding in patients with an 
external conduit from a prior portoenterostomy, or slow gastroin-
testinal blood loss. 
History of ascites was recorded if the patient's medical history 
revealed ascites or ascites was present on physical examination at 
the time of the evaluation. 
A history of coagulopathy was indicated when the patient's 
medical record reported prolonged prothrombin time. 
History of encephalopathy was recorded if frank clinical 
encephalopathy had been diagnosed: an elevated serum NH, 
concentration or abnormal results of psychometric testing did not 
qualify as a positive history of encephalopathy. 
PT and PTPK were either normal. 3 to 5 seconds prolonged 
beyond control. or more than 5 seconds prolonged beyond control. 
Patients with normal PT did not receive vitamin K; however. the 
normal values listed for PTPK included those with a normal PT 
plus those with normalized PT after vitamin K injection. 
II. Variables easily altered. Low serum chloride concentration. 
for example. was a strong indicator of early patient death. This 
variable revealed prognostic significance when the entire group of 
patients (216) was evaluated. and presumably is an indicator of 
both the disturbed fluid and electrolyte state in end-stage liver 
disease and of therapeutic attempts at management of end-stage 
liver disease (in this instance. diuretic therapy). However. the 
referring physician might alter hypochloremia by electrolyte 
replacement. Thus it is conceivable that a patient may falsely have 
absence of the hypochloremia risk factor, in which case the model 
might give erroneous risk. Thus chloride was dropped. as were 
other easily alterable factors. 
STATISTICAL APPENDIX 
I. Cox proportional hazards model. The Cox proportional 
hazards model. lo a semi parametric regression model. assumes that 
the hazard function (i.e., a type of death rate) for the i-th patient 
can be wri Iten as 
h;(t,x, = h.(t)exp(j3'x,) 
where h.(t) is an arbitrary baseline hazard function. j3 is a vector 
of regression coefficients, and )t, is the vector of covariates for the 
i-th patient. It is assumed that the ratio of hazard functions for 
any two patients with different covariates is constant over time 
and that the covariates affect the hazard rate in a multiplicative 
manner. This approach to regression analysis furnishes estimates 
of relative risk between patients with different sets of covari-
ates. 
II. Multiplicative exponential model. To perform the multivari-
ate regression analysis. a multiplicative exponential survival model 
was chosen. 
.- .' 
-'to 
' .. Plots of the log survival versus time were approximately linear, 
indication that the hazard rate is constant over time. which is 
of survival times following an exponential probabil-
distribution. The exponential model is a special case of the 
general Weibull model, which allows the hazard rate to vary 
time. The Wei bull model was also fit to the pretransplanta-
data. but there was no significant difference between the 
~f;llnlenlliD:!ol and Wei bull models, so the simpler exponential model 
chosen. 
We assume that the probability of death at time t for patient i 
;. 1.2, ... ,N) followed an exponential distribution: 
f(t) = Aiexp( -Ait) 
Ai is the hazard rate. Furthermore. we assumed, as in the 
proportional hazards inodel. that the covariates have multi-
effects on the hazard rate of the form Ai = exp(,s' x,), 
,s and Xi are the regression parameters and covariates for 
. i-th patient. respectively. The first element of Xi is I to account 
an intercept. allowing the average hazard rate among patients 
any of the covariates to be estimated also. The cumulative 
I curve at time t for patient i is given by 
Set) = exp(-A,t) 
Thus, knowing the regression parameter ,so one may predict 
based on this model, for a given patient when the 
"""an"",,, are known. 
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III. Formation of multivariate risk scores. The covariates were 
coded as binary indicators of the levels of the four prognostic 
variables; (I) history of ascites (1 if yes, 0 if no); (2) bilirubin 
indirect, with two covariates (level 1. if bilirubin 3 to 6 mg/dL. I; 
if not, 0; le'el 2, if bilirubin was >6 mg/dL, L if not, 0); (3) 
cholesterol (l if <100; 0 if not); and (4) PTT (1 if >20 sec; 0 if 
not). Thus the estimated regression coefficients could be used to 
compute multivariate risk scores. because each coefficient repre-
sents the relative importance of its corresponding covariate in 
terms of risk of dying. The estimated coefficients were -10.01 
(intercept). 1.93 (history of ascites), 1.49 (bilirubin indirect, level 
I), 1.66 (bilirubin indirect, level 2). 1.30 (PTT). and 1.94 
(cholesterol). 
To allow easier calculation of the multivariate risk scores. the 
intercept coefficient was ignored (it was the same for all patients) 
and the other coefficients were divided by the smallest. multiplied 
by 10, and rounded to the nearest integer. By this method the 
relative importance of each of the prognostic variables was 
retained in the scores. but the use of the scores was simplified. This 
method of forming risk groups and creating multivariate risk 
scores is given in Byar." 
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